Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 3,101–3,200 of 3,636
Pandey, A., D'Souza, M. M., Pandey, A. S., & Mir, H. R. (2023) · JMIR Cardio · doi:10.2196/46533 · Cited by 1
CARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
Almeida, A. B., & Horevicht, C. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809
Liu, Y., Wang, W., Cui, X., et al. (2023) · medRxiv · doi:10.1101/2023.07.05.23292277
Genetic Risk Stratification Will Enhance Primary Prevention of Coronary Artery Disease
Roberts, R., & Acuna, E. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.1.4063
Vila, À., Pons, E., García, P. T., Vidal, D., López, S., & Grau, A. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.06.002
The New Fat Kid on the Block: Lipoprotein (a)
Hussein, M. T. E., & Lewis, S. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104731
Novel therapies in clinical use for the management of hyperlipidaemia
Mettananda, C. D. (2023) · Asian Journal of Internal Medicine · doi:10.4038/ajim.v2i2.105
Masson, W. M. (2023) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v26i3.7072
Research Progress of PCSK9 Inhibitors in Lipid-Lowering Therapy
宫, 喜. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381874
Ashton, J. C. (2023) · Open Journal of Clinical and Medical Case Reports · doi:10.52768/2379-1039/2012
“Elimination half-life is 17–20 days and in hyperlipidaemic patients on statins, alirocumab further decreases LDL-C levels and reduces the risk of future cardiovascular events [4,5].”
BackgroundApplication of PCSK9 Inhibitor in Carotid Stenosis
刘, 鑫. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102195
Inclisiran - a new representative of dyslipidemia biological treatment
Karásek, D. (2023) · Klinická farmakologie a farmacie · doi:10.36290/far.2023.020
Boccara, F., Sabouret, P. F., Boileau, C., Georges, J., Leclercq, C., Lesnik, P., & Bruckert, É. (2023) · Panminerva Medica · doi:10.23736/s0031-0808.23.04999-6
Gao, A., Qiu, Z., Wang, Y., Guo, T., Gao, Y., Lu, Q., Yang, Z., Li, Z., Qiu, H., & Gao, R. (2023) · medRxiv · doi:10.1101/2023.10.17.23297180
“6 Aggressive lipid-lowering therapies such as intensified statin treatment or the use of ezetimibe and 7 PCSK9 inhibitors on the basis of statins, have produced positive results and further reduced the 8 risk of recurrent events by 2-15%[5-7].”
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and residual risk
García-Peña, Á. A., Zárate-Correa, L. C., & Monsalve, C. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000212
Novel approaches to the management of hyperlipidaemia
Barton, A. K. (2023) · Prescriber · doi:10.1002/psb.2093
Gao, A., Qiu, Z., Wang, Y., Guo, T., Gao, Y., Lu, Q., Yang, Z., Li, Z., Qiu, H., & Gao, R. (2023) · Research Square · doi:10.21203/rs.3.rs-3471896/v1
Thompson‐Paul, A. M., Sekkarie, A., & Loustalot, F. V. (2023) · American Public Health Association eBooks · doi:10.2105/9780875533377ch14
Cequier, A. R., & Zamorano, J. L. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00012-2
Current Preclinical Applications of Pharmaco-Epigenetics in Cardiovascular Diseases
Papulino, C., Chianese, U., Scisciola, L., Ali, A. H., Barbieri, M., Paolisso, G., Altucci, L., & Benedetti, R. (2023) · Epigenetics and human health · doi:10.1007/978-3-031-42365-9_9
Nuevos fármacos hipolipemiantes
Deibe, F. I. L., Rodríguez, R. D. R., García, M. C., Blanco, C. S., & Peña, P. M. (2023) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2023.04.008
PCSK9 inhibitor therapy: delayed-onset cutaneous reactions
Bukhari, S., Theodoraki, A., Ward, E., et al. (2023) · British Journal of Diabetes · doi:10.15277/bjd.2023.419
Jang, M.-G., Son, Y.-E., Choi, H. D., Kim, J., Kim, T., & Shin, K. (2023) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2023.33.4.270
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_9
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Lupachev, R. M., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2401-02
Place des inhibiteurs du PCSK9 dans le traitement des hypercholestérolémies
Yelnik, C. (2024) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2024.01.014
Nouveautés 2024 des anti-PCSK9
Fayol, A. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.002
Treatment of dyslipidemia in acute coronary syndrome
Yadav, S., & Sawhney, J. P. S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.011 · Cited by 3
“79 Another large RCT that included approximately 19,000 patients 1 – 12 months after ACS studied 80 Both studies also found that lowering LDL-C is better without increased risk of adverse events.”
BackgroundStatine: Nebenwirkungen – alternative Therapieoptionen
Makhmudova, U., & Weingärtner, O. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00669-w · Cited by 1
“Monoklonale Antikörper wie Alirocumab oder Evolocumab zeigen LDL-C-Senkungen um bis zu 60% zusätzlich zu einem Statin [59, 60].”
Impacto de la optimización del tratamiento hipolipemiante en el riesgo cardiovascular residual
Masson, W. M., Barbagelata, L., Masson, G., Lynch, S., Huerin, M. S., & Siniawski, D. A. (2023) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v91.i5.20663
A Family with Familial Hypobetalipoproteinemia Caused by a c.1468C>T in APOB
Tada, H., Kojima, N., Nomura, A., & Takamura, M. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3033-23
Panorama general del riesgo cardiovascular residual
Aristizábal-Colorado, D., Quintero-Zea, K., & Sierra-Castillo, S. (2024) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.1.10357
Management kardiovaskulärer Risikofaktoren
Weiss, N., & Dörr, G. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-61379-5_16-1
A narrative review of treatment modalities for familial hypercholesterolemia
Samprokatsidis, G., Antza, C., Frangou, D., & Kotsis, V. (2023) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1054
Tran, T. T. M., Tran, B. T., Nguyen, M. T., Hong, D. D. T., Nguyen, V. T., Nguyen, N. B. K., Pham, T. T. H., Ho, U. P., Vo, H. L., Luong, T. T. T., et al. (2023) · Tạp chí Y Dược Huế · doi:10.34071/jmp.2023.6.1
Familial Hypercholesterolaemia: Saving Lives Through Early Detection and Intervention
(2024) · The Singapore Family Physician · doi:10.33591/sfp.50.1.u2 · Cited by 1
A Comprehensive Review and Prospects on the Impact of Lipid-Lowering Drugs on Cognitive Functions
韩, 立. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143894
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601258
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601207
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601240
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601162
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601249
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601057
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601267
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601171
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22600997
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601141
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22600970
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601285
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601282
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601000
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601270
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601024
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601036
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601186
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601213
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601225
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22600958
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2023) · UWA Profiles and Research Repository (UWA) · doi:10.6084/m9.figshare.22601087
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.135
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.136
Treatment of dyslipidemia in metabolic syndrome
Vrablík, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.017
How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?
Chen, T., & Liu, N. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000934 · Cited by 1
Eliminate LDL cholesterol after heart attack … but only for a while
Prati, F., Biccirè, F. G., Sammartini, E., & Gatto, L. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae010
“…with Elevated Risk) and Odyssey (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) studies 3,4 have shown that the use of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors in subjects at high cardiovascular risk allows LDL…”
BackgroundThere are those who would like zero LDL cholesterol
Borghi, C., & Bragagni, A. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae012 · Cited by 1
“…from the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) study, 11 it emerged that in a population of patients with recent ACS and already on maximal therapy with a statin and LDLc levels ≥ 70 mg/dL, the addition…”
Clinician Decision Support Tools: Advances in Lipid-Lowering Treatment Intensification
Marvel, F. A., Grant, J. K., & Martin, S. S. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.010884
Symptomatic Intracranial Atherosclerotic Disease
Park, J., & Hong, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-49963-0_20
Dai, Y., Sheng, Y., Zheng, Z., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4804554
Clinical Follow-Up of Patients after Coronary Artery Bypass Grafting
Oliveira, J. C. (2024) · Cardiology and cardiovascular medicine. · doi:10.5772/intechopen.113939
Moderne Strategien zur Lipidsenkung – die frühe Kombinationstherapie
Geiling, J. A., Schulze, P. C., & Weingärtner, O. (2024) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-024-00650-5
Effect of anti-PCSK9 drugs on the association of PCSK9 to LDL
Matteucci, S., Pravatà, V., Esposito, F. M., Pirillo, A., Grigore, L., & Catapano, A. L. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i1.59 · Cited by 1
Chronic Kidney Disease and Cardiovascular Outcomes
Colbert, G. B., Gaur, L., Elrggal, M. E., Madariaga, H. M., & Lerma, E. V. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_16
Cheeley, M. K., & Cavendish, L. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_3
Corral, P., & Cobo, A. L. (2024) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v92.i2.20477
Tada, H., Sakata, K., Usui, S., & Takamura, M. (2024) · Journal of Coronary Artery Disease · doi:10.7793/jcad.30.23-00023
Gurian, A. D. O. V., Teles, A. E. L., Bozi, A., Mantovi, C. K., Moreira, F. G., da Silva, F. M. A., Gonçalves, L. B., Silveira, T. L. D. S., da Silva, T. B., & Lista, P. V. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p121 · Cited by 2
Focused Cardiovascular Risk Assessment and Approaches in Men
Cheung, B., Faruque, S. C., Kim, K., Lam, S., Faaborg-Andersen, C. C., McLaughlin, T. J., Sperling, L. S., & Eapen, D. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_19
Singh, K., Foster, M. W., Violette, M. J., et al. (2024) · medRxiv · doi:10.1101/2024.06.19.24309192
“These include the monoclonal antibodies Alirocumab ( 17 ) and evolocumab ( 18 ) as well as the small interfering RNA (siRNA) Inclisliran ( 19 ).”
BackgroundMinimizing biological risk for novel inhibitory drug targets: One knockout is all you needPreprint
Dimitriev, A., Postovit, L.-M. M., Simpson, A. L., & Wong, G. K. (2024) · medRxiv · doi:10.1101/2024.06.19.24309116
Faut-il traiter une dyslipidémie chez une personne âgée ?
Bordier, L., Cariou, B., & Bauduceau, B. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.06.001
Advances in detection, prevention and treatment of heart failure in type 2 diabetes: part I
Cowley, A., Dattani, A., Brady, E. M., McCann, G. P., & Gulsin, G. S. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.441
A comprehensive retrospect on biomarkers indicating vascular failure
Sakuma, M., Masaki, N., Yano, S., Shimabukuro, M., Yamaoka‐Tojo, M., Fukuda, D., Nakagami, H., Node, K., & Sata, M. (2024) · Vascular Failure · doi:10.30548/vascfail.8.1_24
The Diagnosis and Treatment of Lipid Abnormalities in Pediatric Patients
Degen, M. G., & Hartz, J. C. (2024) · Current Pediatrics Reports · doi:10.1007/s40124-024-00323-9
“Adverse events for both drugs were similar for placebo and study populations, aside from injection site reactions, which were higher in patients receiving the medication in both trials [84].”
The Complexity of Premature Coronary Artery Disease
Noverike, N., Rahimah, A. F., & Rohman, M. S. (2024) · Heart Science Journal · doi:10.21776/ub/hsj.2024.005.03.2 · Cited by 2
Lipidmanagement bei Typ-2-Diabetes mellitus – Strategien zur Risikoreduktion
Brandts, J. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2317-4226
Expertenkonsens, V. V. P. E. G. F. D. K. L. B.-W. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2287-2919
Percorso diagnostico e terapeutico della dislipidemia nel paziente ad alto rischio cardiovascolare
Venturini, E., Casolo, G., Comeglio, M., Fattirolli, F., Limbruno, U., Orso, F., Pino, B. D., Berteotti, M., Angelotti, P., Marcucci, R., et al. (2024) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.23.05196-3
Kim, C.-Y., Lee, J. Y., & Jung, H. W. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-27
“The LDL-C target for patients with ASCVD in the ESC/EAS dyslipidemia guideline is based primarily on recent large-scale trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors which mainly conducted in Western populations (16,17).”
Matin, A., Chaudhry, G.-E.-S., Azra, M. N., Gazali, M., Sung, Y. Y., & Muhammad, T. S. T. (2024) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2024.31.4.2
“…with a history of the acute coronary syndrome and higher atherogenic lipoproteins despite high-intensity or maximum-tolerated-dose statin therapy showed a reduced risk of severe adverse cardiovascular events when treated with alirocumab compared to placebo, as reported by Schwartz et al. (30).”
BackgroundInfluentialŁowicka, W., Graca, M., Szeliga, A., Szostak, A., Korta, K., Oluszczak, K., Szopińska, K., Dyląg, L., Śmigielska-Mikołajczyk, M. J., & Wawszkowicz, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.19.54155 · Cited by 2
Vasiliev, A. P., & Streltsova, N. N. (2024) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20240404
Aragona, C. O., Bianco, A., Caruso, R., Cerulli, M., Cosentino, N., Cittadini, A., Gabriele, M., Mallardo, M., Marini, R., Miserrafiti, B., et al. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.2972 · Cited by 1
Brief Overview of Statins for Lowering Low-Density Lipid Cholesterol
唐, 素. (2024) · Pharmacy Information · doi:10.12677/pi.2024.135050
Pedro‐Botet, J., Freixa‐Pamias, R., Tamarit, J. J., López‐Miranda, J., Fernández-Olmo, R., Muñiz-Grijalvo, O., Vázquez, R., Guijarro, C., Padial, L. R., Díaz-Díaz, J. L., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.08.007
Lee, M., & Safri, A. (2024) · ADCES in Practice · doi:10.1177/2633559x241280315
“13-14 In the GAUSS-2 trial, the comparison between evolocumab and ezetimibe in statin-intolerant patients revealed a lower incidence of myalgia with evolocumab compared to ezetimibe (8% vs 18%).”
Bosch, M., Danés, I., Ballarín, E., et al. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.05.007
Single bolus PCSK9 Inhibition: A new approach to plaque stabilisation
Nicholls, S. J., & Manmathan, G. P. R. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118628
Lipidmanagement bei Typ-2-Diabetes mellitus: Strategien zur Risikoreduktion
Brandts, J. (2024) · Diabetes aktuell · doi:10.1055/a-2401-3884
Ntaios, G., & Dalakoti, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.10.012
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

